PD 151746
目录号 : GC10561An inhibitor of calpain 1
Cas No.:179461-52-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
Cerebellar granule cells |
Preparation method |
The solubility of this compound in DMSO is > 11.6 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition |
20 or 40 μM; 24 hrs |
Applications |
In cerebellar granule cells, pre-treatment with 20 or 40 μM PD 151746 for 24 hrs inhibited calpain and thus, protected neurons against the effect of serum/potassium (S/K) withdrawal, restoring the number of cell survival. Moreover, PD 151746 at the dose of 40 μM inhibited the increase of MEF2 phosphorylation and cdk5/p25 formation, as well as inhibited caspase-3 activity. |
References: [1]. Verdaguer E, Alvira D, Jiménez A, et al. Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons. Br J Pharmacol, 2005, 145(8): 1103-1011. |
PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 μM for μ-Calpain.
Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms. Calpain plays an important role in cell mobility and cell cycle progression.
PD 151746 is a cell-permeable, potent and selective calpain inhibitor. PD151746 significantly inhibited NMDA-induced α-spectrin breakdown product (SBDP) of 145 kDa and completely inhibited the fragmentation of calmodulin-dependent protein kinase II-α (CaMPK-IIα) and nitric oxide synthase (nNOS), which were cleaved by calpain [1]. In cerebellar granule cells, PD151746 inhibited serum/potassium (S/K) withdrawal induced apoptosis by 29% through inhibition of calpain. Also, PD151746 inhibited the increase of MEF2 phosphorylation and cdk5/p25 formation and inhibited caspase-3 activity [2]. In human hepatoma G2 cells, PD151746 significantly reduced insulin-stimulated glycogen synthesis and increased the amount of protein tyrosine phosphatase-ε (PTPε), which suggested that calpain played an important role in regulation of insulin-stimulated glycogen synthesis [3]. In HEK-293 cells expressing human formyl peptide receptor (hFPR) or hFPR-like 1 (hFPRL1), PD151746 increased cytoplasmic free Ca2+ ([Ca2+]i) [4].
References:
[1]. Hajimohammadreza I, Raser KJ, Nath R, et al. Neuronal nitric oxide synthase and calmodulin-dependent protein kinase IIalpha undergo neurotoxin-induced proteolysis. J Neurochem, 1997, 69(3): 1006-1013.
[2]. Verdaguer E, Alvira D, Jiménez A, et al. Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons. Br J Pharmacol, 2005, 145(8): 1103-1011.
[3]. Meier M, Klein HH, Kramer J, et al. Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. J Endocrinol, 2007, 193(1): 45-51.
[4]. Fujita H, Kato T, Watanabe N, et al. Stimulation of human formyl peptide receptors by calpain inhibitors: homology modeling of receptors and ligand docking simulation. Arch Biochem Biophys, 2011, 516(2): 121-127.
Cas No. | 179461-52-0 | SDF | |
化学名 | (Z)-3-(5-fluoro-1H-indol-3-yl)-2-mercaptoacrylic acid | ||
Canonical SMILES | FC1=CC(C(/C([H])=C(S)/C(O)=O)=CN2)=C2C=C1 | ||
分子式 | C11H8FNO2S | 分子量 | 237.25 |
溶解度 | ≥ 11.6mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.215 mL | 21.0748 mL | 42.1496 mL |
5 mM | 0.843 mL | 4.215 mL | 8.4299 mL |
10 mM | 0.4215 mL | 2.1075 mL | 4.215 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。